ETS1 Promotes Aerobic Glycolysis and Growth in Head and Neck Squamous Cell Carcinoma by Targeting RRAS2

Overview

Journal Biochem Genet

Specialty Molecular Biology

Date 2024 Dec 11

PMID 39661306

Authors

Jianguo Liu

Zhi Wang

Xiaoyan Tian

Bingbin Xie

Ke Liu

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignancy with a five-year survival rate below 50%, highlighting the urgent need for novel therapeutic targets. This study explores the role of the small GTPase RRAS2 in HNSCC progression and its regulation of glycolysis. Analysis of data from the TCGA and GTEx databases revealed that RRAS2 is significantly upregulated in HNSCC tissues and is associated with poorer overall patient survival. Functional experiments demonstrated that silencing RRAS2 in HNSCC cell lines inhibits glycolytic activity and cell proliferation while promoting apoptosis, whereas overexpression of RRAS2 enhances glycolysis and cell growth. Additionally, bioinformatics and experimental approaches identified the transcription factor ETS1 as an upstream regulator of RRAS2. ETS1 binds to the RRAS2 promoter, facilitating its transcription and contributing to metabolic reprogramming in HNSCC cells. Rescue experiments confirmed that the ETS1-RRAS2 axis is crucial for maintaining the glycolytic phenotype and proliferative capacity of HNSCC cells. These findings suggest that the ETS1-RRAS2 pathway plays a critical role in HNSCC progression and metabolic adaptation, positioning RRAS2 as a potential therapeutic target for improving patient outcomes.

References

Alarcon B, Martinez-Martin N . RRas2, RhoG and T-cell phagocytosis. Small GTPases. 2012; 3(2):97-101. PMC: 3408983. DOI: 10.4161/sgtp.19138. View

Battaglia M, Sunshine A, Luo W, Jin R, Stith A, Lindemann M . Ets1 and IL17RA cooperate to regulate autoimmune responses and skin immunity to . Front Immunol. 2023; 14:1208200. PMC: 10486983. DOI: 10.3389/fimmu.2023.1208200. View

Becker C, Noldus J, Diamandis E, Lilja H . The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci. 2001; 38(5):357-99. DOI: 10.1080/20014091084236. View

Bhatia A, Burtness B . Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs. 2023; 83(3):217-248. DOI: 10.1007/s40265-023-01835-2. View

Cao Y . Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019; 129(8):3006-3017. PMC: 6668696. DOI: 10.1172/JCI127201. View

Chandel V, Maru S, Kumar A, Kumar A, Sharma A, Rathi B . Role of monocarboxylate transporters in head and neck squamous cell carcinoma. Life Sci. 2021; 279:119709. DOI: 10.1016/j.lfs.2021.119709. View

Chang M, Asthana S, Gao S, Lee B, Chapman J, Kandoth C . Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2015; 34(2):155-63. PMC: 4744099. DOI: 10.1038/nbt.3391. View

Chelakkot C, Chelakkot V, Shin Y, Song K . Modulating Glycolysis to Improve Cancer Therapy. Int J Mol Sci. 2023; 24(3). PMC: 9916680. DOI: 10.3390/ijms24032606. View

Chen J, Fu Y, Day D, Sun Y, Wang S, Liang X . VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis. Nat Commun. 2017; 8(1):383. PMC: 5575285. DOI: 10.1038/s41467-017-00405-x. View

10.

Chen F, Tang C, Yang F, Ekpenyong A, Qin R, Xie J . HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer. Sci Adv. 2024; 10(8):eadk3663. PMC: 10889358. DOI: 10.1126/sciadv.adk3663. View

11.

Choi J, Sebastian C, Ferrer C, Lewis C, Sade-Feldman M, LaSalle T . A unique subset of glycolytic tumour-propagating cells drives squamous cell carcinoma. Nat Metab. 2021; 3(2):182-195. PMC: 7954080. DOI: 10.1038/s42255-021-00350-6. View

12.

Dittmer J . The biology of the Ets1 proto-oncogene. Mol Cancer. 2003; 2:29. PMC: 194255. DOI: 10.1186/1476-4598-2-29. View

13.

Ehrhardt A, Ehrhardt G, Guo X, Schrader J . Ras and relatives--job sharing and networking keep an old family together. Exp Hematol. 2002; 30(10):1089-106. DOI: 10.1016/s0301-472x(02)00904-9. View

14.

Endo T . M-Ras is Muscle-Ras, Moderate-Ras, Mineral-Ras, Migration-Ras, and Many More-Ras. Exp Cell Res. 2020; 397(1):112342. DOI: 10.1016/j.yexcr.2020.112342. View

15.

Ganapathy-Kanniappan S, Geschwind J . Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013; 12:152. PMC: 4223729. DOI: 10.1186/1476-4598-12-152. View

16.

Gu Z, Yao Y, Yang G, Zhu G, Tian Z, Wang R . Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. Sci Transl Med. 2022; 14(661):eabo5987. DOI: 10.1126/scitranslmed.abo5987. View

17.

Gutierrez-Erlandsson S, Herrero-Vidal P, Fernandez-Alfara M, Hernandez-Garcia S, Gonzalo-Flores S, Mudarra-Rubio A . R-RAS2 overexpression in tumors of the human central nervous system. Mol Cancer. 2013; 12(1):127. PMC: 3900289. DOI: 10.1186/1476-4598-12-127. View

18.

Huang C, Chen L, Savage S, Eguez R, Dou Y, Li Y . Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021; 39(3):361-379.e16. PMC: 7946781. DOI: 10.1016/j.ccell.2020.12.007. View

19.

Irfan M, Delgado R, Frias-Lopez J . The Oral Microbiome and Cancer. Front Immunol. 2020; 11:591088. PMC: 7645040. DOI: 10.3389/fimmu.2020.591088. View

20.

Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J . Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1):92. PMC: 7944998. DOI: 10.1038/s41572-020-00224-3. View